| Name | Haleon |
|---|---|
| Epic | HLN |
| Isin | GB00BMX86B70 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 363.30p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £32,890.86 | Debt ratio | n/a |
| Shares in issue | 9,132.30 | Debt-to-equity ratio | n/a |
| P/E ratio | 18.6 | Assets / equity ratio | n/a |
| Total dividends per share | 6.00p | Price to book value | n/a |
| Dividend yield | 1.9 | ROCE | 69.89 |
| Dividend cover | 2.88 | EPS growth | -6 |
| Earning per share | 11.4 | 52-week high / low | 312.05p / 397.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2024-03-14 | 2024-05-16 | 4.20p |
| Interim | 2023-08-24 | 2023-10-05 | 1.80p |
| Final | 2023-03-16 | 2023-04-27 | 2.40p |
| Company name | Haleon |
|---|---|
| Address | Building 5, First Floor, The Heights, Weybridge, Surrey, United Kingdom, KT13 0NY |
| Telephone | +44 (0) 371 384 2227 |
| Website | https://www.haleon.com/ |
| Director | Position |
|---|---|
| Ms Deirdre Mahlan | CEO |
| Mr Brian McNamara | CEO |
| Mr Tobias Hestler | CFO |
| Mr Bryan Supran | Non-Executive Director |
| Mr David Denton | Non-Executive Director |
| Mr Dave Lewis | Non-Executive Chairman |
| Mr Manvinder Singh (Vindi) Banga | Senior Independent Non-Executive Director |
| Ms Dame Vivienne Cox | Independent Non-Executive Director |
| Mr Asmita Dubey | Independent Non-Executive Director |
| Mr Marie-Anne Aymerich | Independent Non-Executive Director |
| Mrs Tracy Jayne Clarke | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 26855 | 28436 | 27195 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 29237 | 30756 | 29200 |
| Inventory / work in progress | 1408 | 1348 | 951 |
| Trade and other receivables | 1947 | 1977 | 2373 |
| Cash and equivalents | 1044 | 684 | 414 |
| Other current assets and asset held for resale | 419 | 50 | 1513 |
| Total of all assets | 34055 | 34815 | 34451 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 4640 | 4370 | 4238 |
| Long term liabilities | 12686 | 13988 | 3733 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 17326 | 18358 | 7971 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 16729 | 16457 | 26480 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 92 | 92 | 1 |
| Minority interests | 123 | 126 | 125 |
| Retained earnings | 27474 | 26730 | 37538 |
| Share premium account | n/a | n/a | n/a |
| Total equity | 16729 | 16457 | 26480 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 1996 | 1825 | 1638 |
| Pre-tax profit | 1628 | 1618 | 1636 |